Vivos Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-5.5M | $-7.7M | $-5.4M | $-5.0M | $-3.9M | $-2.6M | $-1.9M | $-3.8M |
| Depreciation & Amortization | $510.0K | $454.0K | $384.0K | $306.0K | $177.0K | $146.0K | $145.0K | $146.0K |
| Depreciation | $300.0K | $300.0K | $400.0K | $300.0K | $200.0K | $100.0K | $100.0K | $100.0K |
| Amortization | $200.0K | $200.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K |
| Stock-Based Compensation | — | $151.0K | — | — | $317.0K | — | — | $293.0K |
| Net Cash from Operating Activities | $-3.1M | $-6.0M | $-4.2M | $-3.5M | $-3.8M | $-4.2M | $-3.0M | $-2.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $416.0K | $18.0K | $-83.0K | $771.0K | $122.0K | $192.0K | $60.0K | $151.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-18.0K | — | — | $-122.0K | — | — | $-151.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $6.1M | — | — | — | — | — | $3.6M |
| Net Change in Cash | — | $81.0K | — | — | $-3.9M | — | — | $968.0K |
| Free Cash Flow | $-3.6M | $-6.0M | $-4.1M | $-4.3M | $-3.9M | $-4.4M | $-3.1M | $-2.7M |